GASP1 Enhances Malignant Phenotypes of Breast Cancer Cells and Decreases Their Response to Paclitaxel by Forming a Vicious Cycle with IGF1/IGF1R Signaling Pathway

Scientists demonstrated that GASP1 was highly expressed in breast cancers, and patients harboring altered GASP1 showed a worse prognosis than those with wild-type GASP1.